Oksana Suchowersky - Concepedia

Author

Oksana Suchowersky

Also Known As

Erin Furr Stimming, Guy Montreal, Hilary Dubinsky, J. Dobson, Joseph Giuliano, Lesley Brown, Manon Bouchard, O Suchowersky, O. SUCHOWERSKY, O. Suchowersky

258

Publications

11.6K

Citations

H-Index

129

Concepts

All Affiliations

University of Calgary University of Alberta University of Toronto University of British Columbia The University of Sydney

About

Oksana Suchowersky is an author at University of Calgary specializing in medicine, neurology, and parkinson disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	44	4.1K
2	Health Sciences	13	14	930
3	Social Sciences	5	5	363
4	Public Health	4	4	345
5	Behavioral Sciences	1	1	65

Oksana Suchowersky

109

Publications

9.6K

Citations

H-Index

Page 1

	Year	Citations
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial Robert G. Holloway, Ira Shoulson, Karl Kieburtz, JAMA Initial TreatmentParkinson DiseaseMedicineNeuropharmacologyPramipexole Vs Levodopa	2000	802
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion J.-M. Lee, E.M. Ramos, J.-H. Lee, Neurology	2012	384
Practice parameter: Initiation of treatment for Parkinson’s disease: An evidence-based review [RETIRED] Janis M. Miyasaki, W. R. Wayne Martin, Oksana Suchowersky, Neurology Sustained Release LevodopaNeurotherapeuticsPsychotropic MedicationParkinson DiseasePharmacology	2002	375
Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED] Oksana Suchowersky, Stephen G. Reich, Joel S. Perlmutter, Neurology	2006	277
The Canadian multicentre study of deep brain stimulation for cervical dystonia Zelma H. T. Kiss, Kristina Doig-Beyaert, Michael Eliasziw, Brain	2007	254
SOD1 mutation is assosiated with accumulation of neurofilaments in amyotrophic lateral scelaries Guy A. Rouleau, Arthur W. Clark, Karen Rooke, Annals of Neurology	1996	239
Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label results Hubert H. Fernandez, David G. Standaert, Robert A. Hauser, Movement Disorders	2014	236
Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): [RETIRED] Oksana Suchowersky, Gary Gronseth, Joel S. Perlmutter, Neurology	2006	236
Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease I Richard, Roger Kurlan, Caroline M. Tanner, Neurology	1997	230
Predictive testing for Huntington disease in Canada: Adverse effects and unexpected results in those receiving a decreased risk Marlene J. Huggins, Maurice Bloch, Sandi Wiggins, American Journal of Medical Genetics	1992	230

Page 1